SEB Läkemedelsfond D
Equity fund
No data to display ...
1 year
USA
Largest region
Medium
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
Details
- N/A
Investment horizon
- SEB Läkemedelsfond D is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- NAV/Price
10 Feb 2026
- Margin rate
- Start date04 Sept 2025
- ISINSE0024788749
Risk
- Medium (4 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Annual cost
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
Other costs
- Performance-based fee
- Transaction costs
Costs for any currency exchanges are not included.
Allocation
- Stocks 100%Interest 0%
Portfolio
Shows the fund's largest investments.
- Eli Lilly and Co9.1%
- AstraZeneca PLC6.7%
- Merck & Co Inc6.6%
- Johnson & Johnson4.3%
- Thermo Fisher Scientific Inc3.7%
- Novo Nordisk AS Class B3.7%
- Teva Pharmaceutical Industries Ltd ADR3.1%
- Stryker Corp3.1%
- UCB SA2.8%
- Roche Holding AG2.8%